55 Collins Street
Level 38
Melbourne, VIC 3000
Australia
61 3 9639 6036
https://www.mesoblast.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 83
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director | 1.01M | N/A | 1957 |
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) | Gen. Counsel & Corp. Exec. | N/A | N/A | 1968 |
Mr. Michael Schuster M.B.A., MS, BSc, MBA | Head of Pharma Partnering | N/A | N/A | 1977 |
Dr. Eric A. Rose M.D. | Chief Medical Officer & Director | 89.37k | N/A | 1951 |
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA | Head of Regulatory Affairs & Quality Management | N/A | N/A | N/A |
Dr. Fred Grossman D.O., FAPA | Advisor | N/A | N/A | N/A |
Mr. Andrew Chaponnel B.Com. | Interim Chief Fin. Officer | N/A | N/A | N/A |
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. | Chief Operating Officer | N/A | N/A | 1964 |
Mr. Roger D. Brown BA | Head of Spinal Orthopedic Disorders | N/A | N/A | N/A |
Dr. Paul J. Simmons BSc, Ph.D. | Head of Research & New Product Devel. | N/A | N/A | 1959 |
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and GrĂĽnenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Limited’s ISS Governance QualityScore as of June 1, 2022 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 5; Compensation: 10.